menin-mll

Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.

Menin-mll inhibitor 21 is a selective, oral and irreversible Menin inhibitor. Menin-MLL inhibitor 21 promotes selective proliferation of β cells and improvement of β cell function in human islet cultures in vitro. Menin-MLL inhibitor 21 enhances glycemic control in animal models of diabetes. Menin-MLL inhibitor 21 induced a dose-dependent increase in insulin secretion that was augmented by a GLP-1 receptor agonist (RA).

Menin-MLL inhibitor 20 is an irreversible inhibitor of the menin-MLL interaction, exhibiting antitumor activities.

Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.

VTP50469 is a highly selective and orally active small molecule inhibitor of the Menin-MLL protein-protein interaction with potent anti-leukemic activity with a Ki of 104 pM.

MIV-6R inhibits Menin-MLL interaction (IC50: 56 nM) and can be used to study leukemia.

M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia.

MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).

MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM).

MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM.

MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.

Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.

MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM).

MI-503 is an efficient and selective Menin-MLL inhibitor with an IC50 of 14.7 nM. In human MLL leukemia cell lines, MI-503 has a significant growth inhibition effect (GI = 250 nM-570 nM).

Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .

Menin-MLL inhibitor 34 (Compound 37) is a selective and potent inhibitor of Menin-MLL, exhibiting an IC50 of 18.21 nM against Menin. This compound effectively reduces Menin protein levels and downregulates MEN1 transcription, demonstrating sustained anti-leukemia effects.

Menin-MLL inhibitor-25 (compound A6) is a potent inhibitor of the Menin-MLL interaction, with an IC50 of 0.38 µM. It exhibits antiproliferative activity, induces apoptosis and G0/G1 cell cycle arrest, and can reverse differentiation arrest.

Menin-MLL inhibitor 33 (compound 15-a) is a potent Menin-MLL inhibitor, with an IC50 value of 3.6 nM, and exhibits antiproliferative activity.

(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1].

Menin-MLL inhibitor 26 is a Menin-MLL inhibitor. Menin-MLL inhibitor 26 also is an active reference. Menin-MLL inhibitor 26 can inhibits cell growth. Menin-MLL inhibitor 26 can be used for the research of leukemia .

Menin-MLL inhibitor 27 effectively inhibits the interaction between Menin and MLL, serving as a potential tool in cancer research, particularly for acute myeloid leukemia (AML) [1].

Menin-MLL Inhibitor 29 (Compound C1) is a Menin-MLL protein-protein interaction (PPI) inhibitor that demonstrates high affinity to Menin with a dissociation constant (K D) of 138 nM and impedes Menin's interaction with Menin-binding motif 1 (MBM1), as evidenced by an inhibition constant (IC 50) of 46 nM. Additionally, it exhibits anti-proliferative activity against HepG2 and Hep3B hepatoma cell lines with IC 50 values of 0.31 μM and 0.71 μM, respectively, and has been shown to inhibit tumor growth [1].

Menin-MLL inhibitor 31 (compound 18) effectively disrupts the menin-MLL interaction, demonstrating a potent IC 50 value of 4.6 nM [1].

VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity.